Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose abiraterone after docetaxel in metastatic castration-resistant prostate cancer
RBR-5zsczhfPhase 3Completed
- Sponsor
- Liga Contra o Câncer
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abiraterone and prednisone in prostate cancer (PCa) (2 arms), sponsored by Liga Contra o Câncer. Primary endpoint: PSA-based disease progression. Started Feb 2024; status: completed.
02
Drugs
abirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on RBR-5zsczhf.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5zsczhf.